Pharmacy Services
Rosuvastatin (Crestor) - Myopathy and Rhabdomyolysis in Asian-Americans at 40 mg Dose
March 3, 2005
Patients of Asian descent are at increased risk of rhabdomyolysis with high doses of rosuvastatin (Crestor). Drug concentrations are about 2-fold higher than in Caucasian patients.
Astra-Zeneca has changed their product labeling to recommend a 5 mg starting dose for Asian patients and recommend using caution when increasing the dose. Patients receiving cyclosporine therapy, patients with renal insufficiency, and patients who do not require aggressive cholesterol reductions should also receive a 5 mg starting dose to reduce the risk of myopathy and rhabdomyolysis. More details are available at the following links:
- MedWatch Alert:
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm151070.htm - Public Health Advisory:
http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm051756.htm - Revised Product Labeling:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/21366slr005lbl.pdf
Updated
March 3, 2005; University of Utah, Drug Information Service. Copyright 2009, Drug Information Service, University of Utah, Salt Lake City, UT.
Social Media
Copyright © 2013 University of Utah Health Care